BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

• Published in: Clinical & translational oncology Vol. 19; no. 8; pp. 1010 - 1017
• Main Authors: Cuadros, M., Sánchez-Martín, V., Herrera, A., Baliñas, C., Martín-Padrón, J., Boyero, L., Peinado, P., Medina, P. P.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2017
• Subjects: Cell Proliferation; DNA Helicases - genetics; DNA Helicases - metabolism; Gene Expression Regulation, Neoplastic; Humans; Leukemia - genetics; Leukemia - metabolism; Leukemia - pathology; Lymphoma - genetics; Lymphoma - metabolism; Lymphoma - pathology; Medicine; Medicine & Public Health; MicroRNAs - genetics; Nuclear Proteins - genetics; Nuclear Proteins - metabolism; Oncology; Research Article; Transcription Factors - genetics; Transcription Factors - metabolism; Tumor Cells, Cultured; BRG1; miR-155; Leukemia; Prednisolone
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-017-1633-2

Introduction/purpose BRG1 is a key regulator of leukemia stem cells. Indeed, it has been observed that this type of cells is unable to divide, survive and develop new tumors when BRG1 is down-regulated. Materials and methods We assessed BRG1 and miR-155 expression in 23 leukemia cell lines, and two no pathological lymphocyte samples using qPCR. MiR-155 transfection and western blot were used to analyze the relationship between miR-155 and its validated target, BRG1, by measuring protein expression levels. The effect of miR-155 on cell proliferation and prednisolone sensitivity were studied with resazurin assay. Results BRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt’s lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines. To clarify the role of miR-155 in the regulation of BRG1 expression, we administrated miR-155 mimics in different leukemia/lymphoma cell lines. Our results suggest that miR-155 regulate negatively and significantly the BRG1 expression at least in the MOLT4 cell line. Conclusion Our study revealed a previously unknown miR-155 heterogeneity that could result in differences in the treatment with miRNAs in our attempt to inhibit BRG1. However, the expression levels of BRG1 and miR-155, before prednisolone treatment were not statistically significantly associated prednisolone sensitive leukemia cells.